A collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid arthritis (RA); spondyloarthritis (SpA), including ankylosing spondylitis and psoriatic arthritis; juvenile idiopathic arthritis (JIA); or systemic lupus erythematosus (SLE) undergoing elective total hip (THA) or total knee arthroplasty (TKA). Guidelines are as follows:
- RA, SpA including AS and PsA, JIA, and SLE receiving nonbiologic DMARDs: Continue current dose of methotrexate, leflunomide, hydroxychloroquine, and/or sulfasalazine for patients undergoing elective THA or TKA.
- RA, SpA including AS and PsA, JIA, or SLE: Withhold all current biologic agents prior to surgery and plan surgery at end of dosing cycle for that specific medication.
- RA, SpA including AS and PsA, or JIA: Withhold tofacitinib for at least 7 days prior to surgery in patients with RA, SpA including AS and PsA, or JIA.
- Severe SLE: Continue current dose of methotrexate, mycophenolate mofetil, azathioprine, cyclosporine, or tacrolimus through surgical period.
- Not-severe SLE: Withhold current dose of mycophenolate mofetil, azathioprine, cyclosporine, or tacrolimus 1 week prior to surgery.
- RA, SpA including AS and PsA, JIA, or SLE: Restart biologic therapy in patients for whom biologic therapy was withheld prior to undergoing surgery once wound shows evidence of healing, all sutures/staples are out, there is no significant swelling, erythema, or drainage, and there is no clinical evidence of non–surgical site infections.
- RA, SpA including AS and PsA, or SLE: Continue current daily dose of glucocorticoids in adult patients with RA, SpA including AS and PsA, or SLE who are receiving glucocorticoids for their rheumatic condition and undergoing surgery, rather than administering perioperative supra-physiologic glucocorticoid doses.
Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. [Published online ahead of print June 16, 2017]. Arthritis Rheumatol. doi:10.1002/art.40149.
This Week's Must Reads
SLE, Cognitive Impairment, and Lower Income, Lupus, ePub 2018 Feb 21; Meara, Davidson, et al
Understanding Native American Patients with SLE , Lupus Sci Med; ePub 2018 Feb 27; Kheir, et al
RA Linked with Post-Op Surgical Complications, Spine; 2018 ePub Feb 23; Horowitz, et al
Low Muscle Density, Greater Disability Linked in RA, Arthritis Care Res; ePub 2018 Feb 26; Baker, et al
Sputum Antibody Reactivity Is a Marker for RA, Arthritis Rheumatol; ePub 2018 Mar 2; Demoruelle, et al
Must Reads in Clinical Guidelines
Medication Guideline for Patients Undergoing THA, TKA, Arthritis Rheumatol; ePub 2017 Jun 16; Goodman, et al
ACP Updates Guidelines for Osteoporosis, Ann Intern Med; ePub 2017 May 9; Qaseem, et al
Treatment Guidelines for Sjögren’s Syndrome, Arthritis Care Res; ePub 2017 Mar 3; Carsons, et al
ACP Releases Guidelines on Gout Management, Ann Intern Med; 2017 Jan 3; Qaseem, Harris, et al